Physician profile
Sally Huff
NPI 1770193864
$5,586.02
in general payments reported to CMS, 2019-2025
27 companies · $1,621 in 2025
The $1,621 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $905 · 2023: $1,290 · 2024: $1,442 · 2025: $1,621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,352.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,707.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,120.27 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $359.66 | 2022-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $300.62 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $299.77 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $224.91 | 2021-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $209.17 | 2023-2025 | |
| Madrigal Pharmaceuticals | $187.56 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $144.46 | 2023-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $113.90 | 2022-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $113.73 | 2022-2024 | Ocaliva |
| Boston Scientific Corporation | $84.55 | 2023-2025 | Watchman Access System, Watchman Flx |
| Aimmune Therapeutics, INC. | $84.26 | 2024-2025 | Zenpep, Vowst |
| Ferring Pharmaceuticals INC. | $71.99 | 2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $70.32 | 2024-2025 | Iqirvo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $69.73 | 2022-2023 | Injectafer |
| Phathom Pharmaceuticals, INC. | $69.02 | 2024-2025 | Voquezna |
| Genzyme Corporation | $68.01 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $62.28 | 2023 | Idacio |
| Organon LLC | $42.31 | 2023-2024 | Renflexis, Hadlima |
| Ardelyx, INC. | $40.88 | 2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $37.97 | 2023 | |
| Braintree Laboratories, INC. | $33.89 | 2022-2024 | Suflave |
| Merck Sharp & Dohme LLC | $25.70 | 2022-2023 | Dificid |
| Amgen INC. | $15.91 | 2022 | |
| Pfizer INC. | $14.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2024 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.